CDK4/6 inhibitor: a new strategy for endometrial cancer

2022 Fiscal Year Final Research Report

• Project/Area Number: 20K18170
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 56040:Obstetrics and gynecology-related
• Research Institution: Kyoto Prefectural University of Medicine
• Principal Investigator: Yamamoto Takuro 京都府立医科大学, 医学(系)研究科(研究院), 特任助教 (00869787)
• Project Period (FY): 2020-04-01 – 2023-03-31
• Keywords: 子宮体がん / organoid culture

Outline of Final Research Achievements

We　successfully　cultured　uterine　cancer　epithelial　cells　from　tumor　specimens of patients with hormone-sensitive uterine cancer using　organoid　culture. We set up culture conditions for these cultured cells and aimed to establish long-term passaging culture and cell lines. However, the proliferation rate slowed down and the appearance of the cells changed after repeated passages. We were unable to establish a long-term culture of these cells. In addition, although it was necessary to establish a new experimental system for drug evaluation in a culture system that is not a general culture system, we could not establish a stable culture condition and thus could not establish the experimental system. Therefore, it was not possible to study the therapeutic effect of th drug as originally planned.

Free Research Field

Cancer

Academic Significance and Societal Importance of the Research Achievements

子宮体がんの増加に伴い、進行/再発などの予後不良例や妊孕能温存希望例が増加している。化学療法や分子標的薬が試行されているが未だ十分な結果が得られておらず、新たな治療戦略が必要とされている。本研究の目的は、乳がんで長期の効果と安全性が確認されているCDK4/6阻害剤を軸にした新たな治療戦略を乳がんと同じくホルモン依存性腫瘍である子宮体がんにおいて確立をすることである。本研究では、既存の細胞株にはホルモン感受性と言える細胞株が存在しないため、ホルモン感受性子宮体がん株の樹立し、新規治療法の確立を目指した。